trending Market Intelligence /marketintelligence/en/news-insights/trending/kxfzergagsvsghmpuaeflq2 content esgSubNav
In This List

Oasmia completes spin off of veterinary assets to US unit

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Oasmia completes spin off of veterinary assets to US unit

Oasmia Pharmaceutical AB (publ) completed the transfer of its veterinary oncology assets to its U.S.-based subsidiary AdvaVet Inc.

Paccal Vet and Doxophos Vet, drugs for companion animals, were among the assets transferred. Completion of the spin off will allow AdvaVet to start development and commercialization of these two chemotherapy drugs.

AdvaVet is expected to start commercial activities in the U.S. during the second half of 2018.

Sichenzia Ross Ference Kesner LLP served as adviser to Oasmia in the spin off.

Sweden-based Oasmia develops and sells drugs to treat cancer in humans and animals.